News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.

Seed Grant Advances New Dual-Targeted Stomach Cancer Treatment

Drugs that inhibit the tumor-promoting protein HER2 have been used in the treatment of gastric cancer since 2010, and since then, several other tumor biomarkers have emerged that have proven to be effective targets in treating the disease. One such biomarker is Fibroblast Growth Factor Receptor 2b (FGFR2b), a protein that’s estimated to be over-expressed in about 15% of gastric cancer cases.

Could attacking HER2 and FGFR2b simultaneously be an effective new way to treat gastric cancer? And could the tactic work even in patients whose tumors don’t express high amounts of the proteins? One researcher who hopes to answer those questions is Kipp Weiskopf, MD, PhD, Head of Antibody Therapeutics and Biologics in the Cancer Research Institute at Beth Israel Deaconess Medical Center. Weiskopf was recently awarded a $100,000 seed grant from Gastric Cancer Foundation to develop a two-pronged, or “bispecific” antibody drug conjugate (ADC) that he hopes will eventually be tested in people with gastric cancer.

“Bispecific antibodies offer an innovative way to direct therapeutics specifically to cancer cells, wherever they may be in the body, and also minimize the side effects that might occur by limiting damage to normal healthy cells,” Weiskopf explained.

Weiskopf and his colleagues engineered a bispecific ADC targeting HER2 and FGFR2b, and they plan to use their grant to study it in multiple cellular models of gastric cancer. These include tissue samples from gastric tumors that contain high levels of either protein, as well as those that are low in both proteins. They will also test the drug in samples of malignant ascites, fluid that forms in the abdominal peritoneum of some patients. To obtain the ascites samples, Weiskopf’s lab is collaborating with former American Gastroenterology Association-Gastric Cancer Foundation Ben Feinstein Memorial Research Scholar Award winner Samuel Klempner, MD, of Harvard Medical School and Massachusetts General Hospital. In the final phase of the project, Weiskopf will test the drug in mouse models of gastric cancer.

In preliminary studies, Weiskopf’s team discovered that the ADC they designed was effective at killing cancer cells with low levels of FGFR2b and HER2. They will continue to test their hypothesis that the drug could work to shrink tumors with low or moderate expression of both biomarkers, in the hopes of demonstrating it could be effective for the majority of gastric cancer patients. They have an ambitious goal of demonstrating that the drug will be ready to test in patients in three years. “We designed our therapeutic to be ready to advance into clinical trials, and we hope to be able to move quickly to get it to patients,” he said.

Weiskopf earned his MD and PhD at Stanford University, where his research focused on targeting the innate immune system to attack and eliminate cancer cells. He zeroed in on macrophages, large white blood cells that are often prevalent in solid tumors, including stomach cancer. These cells have the ability to attack gastric cancer cells, but they are frequently inhibited by immune checkpoints—a problem he wanted to tackle. “My initial motivation for developing bispecific antibodies was to stimulate and provoke multiple mechanisms for targeting cancer cells, while also engaging the immune system,” he said.

The Gastric Cancer Foundation is committed to supporting scientists who are pursuing research that could result in novel diagnostics and treatments for patients. Our seed grants help researchers generate the preliminary data they need to apply for larger grants or attract commercial partners to advance their projects. This year, the Foundation also awarded a $100,000 seed grant to Andrew Song, PhD, assistant professor in translational molecular pathology at University of Texas MD Anderson Cancer Center, who is using artificial intelligence to develop a 3D framework for predicting which stomach lesions are most at risk for progressing to gastric cancer.

Weiskopf expressed his gratitude to Gastric Cancer Foundation’s donors for providing critical funding for early-stage research.

“This grant is tremendously important for our lab and for being able to advance this work forward towards the clinic,” he said. “With this funding, we can move quickly and realistically in a short time frame to advance a therapeutic that we really think could be transformative for patients.”

X